Sequential systemic administrations of combretastatin A4 phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on scid mice carrying bifocal tumor xenografts

Theranostics

Volumn 3, Issue 2, 2013, Pages 127-137

  Li, Junjie ^a,b   Cona, Marlein Miranda ^a,b   Chen, Feng ^a,b   Feng, Yuanbo ^a,b   Zhou, Lin ^a   Zhang, Guozhi ^a   Nuyts, Johan ^a   de Witte, Peter ^c   Zhang, Jian ^d   Yu, Jie ^a   Oyen, Raymond ^a   Verbruggen, Alfons ^c   Ni, Yicheng ^a,b,d  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b KU Leuven   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Laboratory of Translational Medicine   (China)

Author keywords

Necrosis targeting radiotherapy; Radiation induced fibrosarcoma 1 (RIF 1); Survival; Synergistic antitumor effects; Vascular disrupting agents (VDAs)

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; HYPERICIN; HYPERICIN I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PERYLENE; RADIOACTIVE IODINE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE SEQUENCE; DRUG MONITORING; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; EX VIVO STUDY; FIBROSARCOMA; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CYTOCHEMISTRY; DISEASE MODEL; HUMAN; INTRAVENOUS ADMINISTRATION; MOUSE MUTANT; NECROSIS TARGETING RADIOTHERAPY; PATHOLOGY; RADIATION-INDUCED FIBROSARCOMA-1 (RIF-1); RADIOGRAPHY; SURVIVAL; SYNERGISTIC ANTITUMOR EFFECTS.; VASCULAR DISRUPTING AGENTS (VDAS); XENOGRAFT;

NECROSIS TARGETING RADIOTHERAPY; RADIATION-INDUCED FIBROSARCOMA-1 (RIF-1); SURVIVAL; SYNERGISTIC ANTITUMOR EFFECTS.; VASCULAR DISRUPTING AGENTS (VDAS);

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; FIBROSARCOMA; HISTOCYTOCHEMISTRY; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, SCID; PERYLENE; RADIONUCLIDE IMAGING; STILBENES; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880937489     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5790     Document Type: Article

References (26)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889; 1:571-573.
2. Kuonen F, Secondini C, Ruegg C. Molecular Pathways: Emerging pathways mediating growth, invasion and metastasis of tumors progressingin an irradiated microenvironment. Clin Cancer Res. 2012;18(19):5196-202.
3. Ni Y, Van de Putte M, de Witte P, et al. Targeted radiotherapy. European patent EP2219683B1, Date of publication 2012; Priority: 26.11.2007.
4. Li J, Sun Z, Zhang J, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011; 260: 799-807.
5. Li J, Cona MM, Chen F, et al. Exploring Theranostic Potentials of Radioiodinated Hypericin in Rodent Necrosis Models. Theranostics. 2012; 2: 1010-1019.
6. Li J, Chen F, Cona MM, et al. A review on various targeted anticancer therapies. Target Oncol. 2012; 7: 69-85.
7. Brown J, Giaccia A. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58: 1408-16.
8. Dark G, Hill S, Prise V, et al. Combretastatin A-4 agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 1829-34.
9. Van de Putte M, Marysael T, Fonge H, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer. 2012; 131(2): 129-37.
10. Ozono S, Miyao N, Igarashi T, et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol.2004; 34:82-5.
11. Fonge H, Van de Putte M, Huyghe D, et al. Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging. 2007; 2: 113-9.
12. Fonge H, Vunckx K, Wang H, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J. 2008; 29: 260-9.
13. Van de Putte M, Wang H, Chen F, de Witte P, Ni Y. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol. 2008; 15:107-13.
14. Bormans G, Huyghe D, Christiaen A, et al. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J. Labelled Compd. Radiopharm.2004; 47: 191-198.
15. Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis avid tracer agent. Eur J Nucl Med Mol. 2006; 33:595-601.
16. Ni Y. MR Contrast agents for cardiac imaging. In: Bogaert J, Dymarkowski S, Taylor A, Muthurangu V, eds. Clinical Cardiac MRI. Berlin Heidelberg: Springer-Verlag. 2012:31-51.
17. Shaked Y, Kerbel R. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res.2007; 67:7055-8.
18. Koljenovic S, Choo-Smith L, Bakker Schut T, et al. Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by raman spectroscopy. Laboratory Investigation.2002; 82: 1265-1277.
19. Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. J Cancer Res Clin Oncol.2011; 137:1619-27.
20. Tozer G, Kanthou C, Lewis G, et al. Tumor vascular disrupting agents: combating treatment resistance. Br J Radiol. 2008; 81:S12-20.
21. Dziba J, Marcinek R, Venkataraman G, Robinson J, Ain K. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid. 2002; 12: 1063-70.
22. Dong D, Ko B, Baumeister P, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res.2005; 65: 5785-91.
23. Chen B, Roskams T, de Witte P. Enhancing the antitumoral effect of hypericin-mediated photodynamic therapy by hyperthermia. Lasers Surg Med. 2002; 31:158-63.
24. Li J, Cona MM, Feng Y, et al. A Single-dose Toxicity Study in Mice on Non-radioactive Iodinated Hypericin for a Targeted Anticancer Therapy. Acta Pharmacologica Sinica. 2012; 33:1549-56.
25. Cona MM, Li JJ, Chen F, et al. A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [Iodogen] dissolved in dimethyl sulfoxide [DMSO]. XENOBIOTICA. 2013; [Epub ahead of print].
26. Li J, Oyen R, Verbruggen A, Ni Y. Small Molecule Sequential Dual- Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. J Cancer. 2013; 4: 133-145.